PolyModels Hub, based in London, has successfully raised £1.1 million in seed funding. This funding aims to accelerate the digital transformation of pharmaceutical process development, which remains rooted in traditional practices.
The funding, led by Marathon Venture Capital, is a testament to the growing interest in modernising pharma processes. Amid the urgency for new drugs, PolyModels Hub’s innovative approach can significantly cut down time-to-market, offering hope for faster therapeutic breakthroughs.
The newly acquired £1.1 million will empower PolyModels Hub to expand both its workforce and the capabilities of its ambitious product roadmap. An urgent need drives this expansion, propelled by the escalating demand for their cutting-edge solutions. Alex Alexakis of Marathon Venture Capital highlights the transformative potential of modern technologies such as AI, which, when integrated into pharma development, could expedite the delivery of new therapies to a global market.
PolyModels Hub ambitiously tackles these challenges with its comprehensive digital platform. Their solution ensures that even with limited experimental data, the right modelling approaches can be identified, vastly improving process outcomes.
The vision is empowering scientists with AI tools, offering insights across every stage of transforming chemical compounds into viable drugs —all within an interactive platform dedicated to pharmaceutical excellence.
It assists stakeholders in collaboratively developing models that significantly impact the creation of new drugs or optimisation of existing ones, leveraging the platform’s streamlined workflows to empower decision-making.
Antonio Yankey, Co-founder & Director of Tech & Product, emphasises upcoming enhancements. These include AI integrations to identify optimal tools swiftly, thus boosting efficiency and precision. Additionally, expanding the team with top talent is pivotal to sustaining their innovative trajectory.
Their dedication to integrating cutting-edge technology with traditional pharmaceutical expertise places them in an influential position to guide future industry standards.
PolyModels Hub is at the forefront of a digital revolution in pharma process development. Their funding success and innovative platform development indicate a bright trajectory, paving the way for quicker delivery of critical therapies.
The financial boost will enable PolyModels Hub to refine their ModelFlow platform and expand their reach, making significant strides in digitalising pharmaceutical processes. Their commitment to innovation heralds a new era of efficiency in drug development.
As PolyModels Hub continues to integrate advanced AI and simulation strategies, their influence on how quickly and effectively medicines can be developed and delivered will be profound, setting new industry benchmarks.
